BioIntelliSense

BioIntelliSense provides medical-grade continuous health monitoring and COVID-19 screening at scale. Their proprietary FDA-cleared BioSticker™ and medical-grade BioButton™ wearable devices and algorithmic data services provide clinical intelligence that sets a new standard in Remote Patient Monitoring (RPM). In response to the COVID-19 pandemic, BioIntelliSense accelerated the development and launch of its COVID-19 solution to facilitate the detection of signs and symptoms of an early infectious process for safe return to work, school, travel, and events.

The BioIntelliSense Data-as-a-Service (DaaS) platform also includes the BioHub™, a cellular 5G-enabled gateway designed for seamless and secure Bluetooth wireless data transmission to the BioCloud for advanced analytics. The BioSticker and BioButton wearable devices are also compatible with BioMobile, an iOS and Android downloadable app, conveniently offering a range of deployment options for RPM programs.

The initial challenge BioIntelliSense faced was integrating JSON device data into Epic via HL7 for a leading healthcare system in Colorado. “We needed a technology partner who understood the regulated medical device industry and could meet a diverse set of data integration requirements,” said Mike Hawn, SVP Data Services & Product Solutions for BioIntelliSense.

After evaluating integration solutions, BioIntelliSense selected the Envoy iPaaS from Rhapsody. “We wanted a cloud-based option and a partner who knew health integration, so our engineers could focus on one pipe and one protocol to get data to the integration engine, and then trust that service to securely share the data downstream with our clients,” Hawn said.

Additionally, BioIntelliSense required a technology partner who could keep pace with their growth and integrate with a diverse set of enterprise systems, including EHR systems, RPM applications, telehealth solutions, and clinical trial platforms.

“We occasionally encounter clients or partners with limited integration resources and systems that rely on data exchange that is FTP-based,” Hawn explained. “To have Rhapsody pull up a comma delimited file, massage it, and hit our JSON APIs, without any engineers having to be involved on our side, is very efficient.”

Leveraging Rhapsody capabilities, BioIntelliSense was able to successfully integrate with a leading EHR’s environment along with more than 20 best-in-class RPM applications and telehealth solutions to address the COVID-19 pandemic and medical-grade care at home. BioIntelliSense is uniquely positioned to address virtual care strategies and the demand for hospital-to-home programs with existing and planned enterprise-grade integrations, supported by Rhapsody, that are designed to accelerate and scale deployments for providers and health plans.

This diagram below illustrates how BioIntelliSense uses Envoy iPaaS to simplify complex data mapping and normalization. Envoy ingests the data in many formats from varying transport methods and transforms it for use in the BioIntelliSense REST API. The process is the same in reverse. BioIntelliSense sends data back in the format customers require it through mapping done in Envoy.

The following use case scenarios further illustrate the combined Rhapsody and BioIntelliSense capabilities and value:

The BioButton COVID-19 Screening solution provides an added layer of safety and protection in managing return to work, school, travel, and events. Enterprise organizations nationally, along with the Saint Lucia Ministry of Health, have selected the BioButton COVID-19 screening solution to monitor for signs and symptoms of an early infectious process, as illustrated in the workflow on the right.

Building Rhapsody into the BioIntelliSense platform architecture from the beginning, allows for repeatable use case across multiple clients and market segments.

Philips, BioIntelliSense, and University of Colorado have received U.S. Department of Defense funding for early COVID-19 detection. The 2,500-person clinical trial is designed to validate BioIntelliSense FDA-cleared BioSticker device for the early detection of COVID-19 symptoms. The goal is to accelerate the use of wearable diagnostics for the benefit of military and public health through the early identification and containment of pre-symptomatic COVID-19 cases. BioIntelliSense is leveraging Rhapsody capabilities to automate the ordering and distribution of its BioSticker and BioHub devices to study participants, as illustrated in the workflow to the right.